

Southport & Formby CCG – FOI 48320

Could you please provide me with the Southport & Formby CCG Medicines Management/Medicines Optimisation/Prescribing Cost Improvement/Cost Savings Plan for the current year.

SFCCG Predicted QIPP Saving 2018/19 - £1,017,000

Primary Care QIPP Savings Plan

| QIPP Area | Comment | Predicted Annual Saving |
|--|--|-------------------------|
| Individual Patient Reviews (Ann Savings) | QIPP drug Switch Savings, Stop Start patient reviews, Care home and Virtual Ward patient review savings. CD MR drugs etc | £147k |
| Respiratory Review | 10mth Optimise inhaler choice as per Pan Mersey APC guidancel | £213k |
| Blood Glucose Products | Figure based on Switching to BD Viva or Neo verifine | £30k |
| Restricted Items | Products of low Clinal Effectivness, Clinically effective products where more cost effective products are available and Products that are low priority for NHS Funding. Data to be reviewed via EPACT focus on 18 specific treatments. | £229k |
| Rebate Schemes | Including rebates for Seretide, Airflusal, Mezolar Matrix, Edoxaban, Degarelix, Zoladex, Spiolto, GlucoRx Fine, GlucoMen & Contour Next Strips | £111k |
| Optimise Medicines Optimisation | Cost Avoidance Optimise Rx Savings based on savings achieved in 17/18 Qipp achievement | £85k |
| Gluten Free Products | National guidance actioned | £15k |
| Over the Counter and Self Care Medicines | Calculated from introduction of CCG Medicines Self Care Policy for Self-Limiting and/or Minor Ailments | £10k |
| Dermatology Products | Optimisation of emollients and review via Pan Mersey of Bath/Shower products and Barrier Creams. | £11k |

Community/Primary Care QIPP Savings Plan

| | | |
|---------------------|--|------|
| Wound Care Products | Joint Working with Community Provider. Introduction of Nursing Home dressing service via community Pharmacy. | £70k |
|---------------------|--|------|

Secondary Care QIPP Savings Plan

| | | |
|---------------------------------|---|------|
| High Cost Drugs and Biosimilars | Optimise use of biosimilars and assurance systems | £96k |
|---------------------------------|---|------|